12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Soliris eculizumab: Interim data

Alexion said interim data from an open-label, German trial showed that Soliris for 8 weeks "substantially improved" serious morbidities in patients with STEC-HUS. Specifically, 95% of patients achieved a global response, 94% had improved kidney function, 85% had improved neurologic function and 100%...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >